Jefferies & Company has published a research report on Regeneron Pharmaceuticals REGN after after Ophthotech data was reported.
In the report, Jefferies writes, "Ophthotech, a privately-held biotech, reported positive PIIb data earlier this morning with the combination of Fovista and Lucentis v. Lucentis alone. Given strong appreciation in REGN shares, any news of upcoming competition may lead to weakness in REGN shares/possible profit taking. However, we believe that Fovista (if/when approved) could be administered with any anti-VEGF agent including Eylea."
Jefferies maintains its Buy rating and $161 price target on Regeneron, which is currently trading down $7.08 from yesterday's $127.85 closing price.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in